Eczema laboratory findings

Jump to navigation Jump to search

Eczema Microchapters


Patient Information


Historical Perspective




Differentiating Eczema from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Social Impact

Future or Investigational Therapies

Case Studies

Case #1

Eczema On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Eczema

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eczema

CDC on Eczema

Eczema in the news

Blogs on Eczema

Directions to Hospitals Treating Eczema

Risk calculators and risk factors for Eczema

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.


Doing a routine laboratory testing for eczema is not mandatory. Although an elevated Level of IgE is associated with eczema, it is not specific to this disease. Several other medical conditions manifest with elevated IgE levels such as allergy, parasitic infections, autoimmune diseases, and certain carcinomas. [1] [2] [3] [4]

Laboratory Findings


  1. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL; et al. (2014). "Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis". J Am Acad Dermatol. 70 (2): 338–51. doi:10.1016/j.jaad.2013.10.010. PMC 4410183. PMID 24290431.
  2. Kabashima K (2013). "New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity". J Dermatol Sci. 70 (1): 3–11. doi:10.1016/j.jdermsci.2013.02.001. PMID 23473856.
  3. Murat-Susić S, Lipozencić J, Zizić V, Husar K, Marinović B (2006). "Serum eosinophil cationic protein in children with atopic dermatitis". Int J Dermatol. 45 (10): 1156–60. doi:10.1111/j.1365-4632.2006.02865.x. PMID 17040428.
  4. Schulte-Herbrüggen O, Fölster-Holst R, von Elstermann M, Augustin M, Hellweg R (2007). "Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis". Int Arch Allergy Immunol. 144 (3): 211–6. doi:10.1159/000103994. PMID 17579279.
  5. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C; et al. (2012). "Guidelines for treatment of atopic eczema (atopic dermatitis) part I." J Eur Acad Dermatol Venereol. 26 (8): 1045–60. doi:10.1111/j.1468-3083.2012.04635.x. PMID 22805051.
  6. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J; et al. (2013). "Atopic dermatitis: a practice parameter update 2012". J Allergy Clin Immunol. 131 (2): 295-9.e1-27. doi:10.1016/j.jaci.2012.12.672. PMID 23374261.